CA2817336A1 - Succinate de solifenacine cristallin - Google Patents

Succinate de solifenacine cristallin Download PDF

Info

Publication number
CA2817336A1
CA2817336A1 CA2817336A CA2817336A CA2817336A1 CA 2817336 A1 CA2817336 A1 CA 2817336A1 CA 2817336 A CA2817336 A CA 2817336A CA 2817336 A CA2817336 A CA 2817336A CA 2817336 A1 CA2817336 A1 CA 2817336A1
Authority
CA
Canada
Prior art keywords
solifenacin succinate
crystalline
succinate
axial ratio
particle size
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2817336A
Other languages
English (en)
Inventor
Max Born
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hexal AG
Original Assignee
Hexal AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hexal AG filed Critical Hexal AG
Publication of CA2817336A1 publication Critical patent/CA2817336A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CA2817336A 2010-11-11 2011-11-11 Succinate de solifenacine cristallin Abandoned CA2817336A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP10014527 2010-11-11
EP10014527.5 2010-11-11
PCT/EP2011/069969 WO2012062916A1 (fr) 2010-11-11 2011-11-11 Succinate de solifénacine cristallin

Publications (1)

Publication Number Publication Date
CA2817336A1 true CA2817336A1 (fr) 2012-05-18

Family

ID=43663592

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2817336A Abandoned CA2817336A1 (fr) 2010-11-11 2011-11-11 Succinate de solifenacine cristallin

Country Status (3)

Country Link
EP (1) EP2638039A1 (fr)
CA (1) CA2817336A1 (fr)
WO (1) WO2012062916A1 (fr)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO2005012I1 (no) 1994-12-28 2005-06-06 Debio Rech Pharma Sa Triptorelin og farmasoytisk akseptable salter derav
US20080287680A1 (en) 2004-02-09 2008-11-20 Astellas Pharma Inc. Solifenacin Succinate-Containing Composition
WO2005087231A1 (fr) 2004-03-16 2005-09-22 Astellas Pharma Inc. Composition contenant de la solifenacine
US20080103171A1 (en) 2004-12-27 2008-05-01 Astellas Pharma Inc. Stable Particular Pharmaceutical Composition of Solifenacin or Salt Thereof
US20080114028A1 (en) 2006-07-24 2008-05-15 Tamas Koltai Process for preparing polymorphic forms of solifenacin succinate
JP2010523539A (ja) 2007-03-30 2010-07-15 メディチェム ソシエダ アノニマ ソリフェナシンの改良された合成法
JP2009538362A (ja) 2007-07-13 2009-11-05 テバ ファーマシューティカル インダストリーズ リミティド ソリフェナシンの調製方法
ITMI20080195A1 (it) 2008-02-08 2009-08-09 Dipharma Francis Srl Procedimento per la preparazione di solifenacin
WO2009139002A2 (fr) 2008-05-12 2009-11-19 Msn Laboratories Limited Procédé perfectionné de fabrication de solifénacine et de ses sels pharmaceutiquement acceptables
PL3067353T3 (pl) * 2008-07-29 2018-04-30 Krka, D.D., Novo Mesto Sposób wytwarzania soli solifenacyny i ich włączenie do farmaceutycznych postaci dawkowania

Also Published As

Publication number Publication date
WO2012062916A1 (fr) 2012-05-18
EP2638039A1 (fr) 2013-09-18

Similar Documents

Publication Publication Date Title
US11603363B2 (en) Crystalline form of LNP023
JP6603306B2 (ja) ドルテグラビルナトリウムの新規な水和物
EP3524234B1 (fr) Formes à l'état solide de sofosbuvir
KR20170126016A (ko) 아픽사반 제제
EP2579858B1 (fr) Composition pharmaceutique contenant de l'ivabradine
SK76999A3 (en) Composition based on ziprasidone, method for treating psychoses and process for preparing big crystals of ziprasidone
JP5757492B2 (ja) 製剤用核粒子
EP3653599B1 (fr) Phosphate tapentadol cristallin
JP2020521732A (ja) Ｎ−｛４−［（６，７−ジメトキシキノリン−４−イル）オキシ］フェニル｝−ｎ’−（４−フルオロフェニル）シクロプロパン−１，１−ジカルボキサミドの塩の結晶性固体形態、製造プロセス、及び使用方法
KR101663838B1 (ko) 물 격리제를 사용한 습윤 과립화법
FI107878B (fi) Farmaseuttinen menetelmä
UA125938C2 (uk) Кристалічна форма n-бутилдеоксигалактоноджириміцину
EP0064388B1 (fr) Compositions pharmaceutiques orales à effet retardé
RS56898B1 (sr) Čvrsti oblici soli alfa-6-mpeg6-o-hidroksikodona kao opioidni agonisti i njihove upotrebe
CA2817336A1 (fr) Succinate de solifenacine cristallin
DE602004010837T2 (de) Pharmazeutische zusammensetzung auf basis eines idazoxan-salzes oder eines seiner polymorphen
CN102199161B (zh) 一种苯磺酸氯吡格雷晶型ⅰ及其制备方法和用途
WO2017045742A1 (fr) Formulation à libération retardée contrôlée du principe actif
JP5585920B2 (ja) 粒子状製剤
AU2017228681B2 (en) Apixaban formulations
CN102120746B (zh) 一种盐酸氯吡格雷晶型ⅱ及其制备方法和用途
CN102010423B (zh) (S)-α,α-[(2-氯苯基)-(4,5,6,7-四氢噻吩并[3,2-c]吡啶-5-基)]-N′-(二甲基)甲叉基)乙酰肼的晶型Ⅱ及其制备方法
WO2020136095A1 (fr) Composition pharmaceutique comprenant des agglomérats sphériques de timapiprant
CN102285996A (zh) 一种苯磺酸氯吡格雷晶型ⅱ及其制备方法和用途
SK50532006A3 (sk) Tablety hydrobromidu citalopramu

Legal Events

Date Code Title Description
FZDE Dead

Effective date: 20161114